Zoetis
About: Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Employees: 13,800
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
7% more funds holding in top 10
Funds holding in top 10: 14 [Q1] → 15 (+1) [Q2]
2.42% more ownership
Funds ownership: 92.44% [Q1] → 94.86% (+2.42%) [Q2]
8% more first-time investments, than exits
New positions opened: 149 | Existing positions closed: 138
5% more call options, than puts
Call options by funds: $248M | Put options by funds: $236M
0% more repeat investments, than reductions
Existing positions increased: 725 | Existing positions reduced: 725
4% less capital invested
Capital invested by funds: $68.1B [Q1] → $65.7B (-$2.39B) [Q2]
1% less funds holding
Funds holding: 1,866 [Q1] → 1,843 (-23) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Argus Research
Jasper Hellweg
|
$190
|
Buy
Reiterated
|
9 Sep 2025 |
Piper Sandler
David Westenberg
|
$215
|
Overweight
Maintained
|
11 Aug 2025 |
Leerink Partners
Daniel Clark
|
$155
|
Market Perform
Downgraded
|
17 Jul 2025 |
Stifel
Jonathan Block
|
$160
|
Hold
Downgraded
|
18 Jun 2025 |
Financial journalist opinion
Based on 10 articles about ZTS published over the past 30 days